Relmada Therapeutics (RLMD) Change in Account Payables (2012 - 2026)
Relmada Therapeutics (RLMD) reported Change in Account Payables of $1.8 million for Q1 2026, up 161.5% year-over-year from $673967.0 in Q1 2025, and up 1421.43% on a QoQ basis from $115842.0 in Q4 2025.
Relmada Therapeutics (RLMD) has 15 years of Change in Account Payables data on file, last reported at $1.8 million in Q1 2026.
- Quarterly Change in Account Payables rose 161.5% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (up 152.66% YoY) and the FY2025 annual result came in at -$2.6 million, down 510.15% from the prior year.
- Change in Account Payables advanced to $1.8 million in Q1 2026 per RLMD's latest filing, from $115842.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $3.2 million in Q2 2022 and bottomed at -$3.5 million in Q3 2022.
- The 5-year median for Change in Account Payables is $96901.0 (2025), against an average of -$88793.8.
- Peak annual rise in Change in Account Payables reached 300.38% in 2024, while the deepest fall reached 335.04% in 2024.
- Tracing RLMD's Change in Account Payables over 5 years: stood at $1.2 million in 2022, then sank by 45.33% to $649257.0 in 2023, then soared by 174.93% to $1.8 million in 2024, then tumbled by 93.51% to $115842.0 in 2025, then soared by 1421.43% to $1.8 million in 2026.
- Per Business Quant, the three latest RLMD Change in Account Payables figures stand at $1.8 million (Q1 2026), $115842.0 (Q4 2025), and $91191.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | 1.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.76 Mn |
| Mar 31, 2026 | 1.76 Mn |
| Dec 31, 2025 | 115,842.00 |
| Dec 31, 2025 | 115,842.00 |
| Sep 30, 2025 | 91,191.00 |
| Sep 30, 2025 | 91,191.00 |
| Jun 30, 2025 | 96,901.00 |
| Jun 30, 2025 | 96,901.00 |
| Mar 31, 2025 | -2.87 Mn |
| Mar 31, 2025 | -2.87 Mn |
| Dec 31, 2024 | 1.79 Mn |
| Dec 31, 2024 | 1.79 Mn |
| Sep 30, 2024 | -1.83 Mn |
| Sep 30, 2024 | -1.83 Mn |
| Jun 30, 2024 | -1.01 Mn |
| Jun 30, 2024 | -1.01 Mn |
| Mar 31, 2024 | 1.68 Mn |
| Mar 31, 2024 | 1.68 Mn |
| Dec 31, 2023 | 649,257.00 |
| Dec 31, 2023 | 649,257.00 |
| Sep 30, 2023 | -2.00 Mn |
| Sep 30, 2023 | -2.00 Mn |
| Jun 30, 2023 | 431,651.00 |
| Jun 30, 2023 | 431,651.00 |
| Mar 31, 2023 | -839,971.00 |
| Mar 31, 2023 | -839,971.00 |
| Dec 31, 2022 | 1.19 Mn |
| Dec 31, 2022 | 1.19 Mn |
| Sep 30, 2022 | -3.47 Mn |
| Sep 30, 2022 | -3.47 Mn |
| Jun 30, 2022 | 3.22 Mn |
| Jun 30, 2022 | 3.22 Mn |
| Mar 31, 2022 | -522,353.00 |
| Mar 31, 2022 | -522,353.00 |
| Dec 31, 2021 | -1.52 Mn |
| Dec 31, 2021 | -1.52 Mn |
| Sep 30, 2021 | 2.25 Mn |
| Sep 30, 2021 | 2.25 Mn |
| Jun 30, 2021 | 2.37 Mn |
| Jun 30, 2021 | 2.37 Mn |
| Mar 31, 2021 | -263,679.00 |
| Mar 31, 2021 | -263,679.00 |
| Dec 31, 2020 | 7.62 Mn |
| Dec 31, 2020 | 7.62 Mn |
| Sep 30, 2020 | -236,536.00 |
| Sep 30, 2020 | -236,536.00 |
| Jun 30, 2020 | -137,647.00 |
| Jun 30, 2020 | -137,647.00 |
| Mar 31, 2020 | 580,153.00 |
| Mar 31, 2020 | 580,153.00 |
| Dec 31, 2019 | -401,696.00 |
| Dec 31, 2019 | -401,696.00 |
| Sep 30, 2019 | 342,189.00 |
| Sep 30, 2019 | 342,189.00 |
| Jun 30, 2019 | 565,468.00 |
| Jun 30, 2019 | 565,468.00 |
| Mar 31, 2019 | 721,220.00 |
| Mar 31, 2019 | 721,220.00 |
| Dec 31, 2018 | -1.31 Mn |
| Dec 31, 2018 | -1.31 Mn |
| Sep 30, 2018 | 253,918.00 |
| Sep 30, 2018 | 253,918.00 |
| Mar 31, 2018 | 805,526.00 |
| Mar 31, 2018 | 805,526.00 |
| Dec 31, 2017 | -89,485.00 |
| Dec 31, 2017 | -89,485.00 |
| Sep 30, 2017 | -232,510.00 |
| Sep 30, 2017 | -232,510.00 |
| Jun 30, 2017 | 194,127.00 |
| Jun 30, 2017 | 194,127.00 |
| Mar 31, 2017 | 28,196.00 |
| Mar 31, 2017 | 28,196.00 |
| Dec 31, 2016 | -364,484.00 |
| Dec 31, 2016 | -364,484.00 |
| Sep 30, 2016 | -587,992.00 |
| Sep 30, 2016 | -587,992.00 |
| Jun 30, 2016 | 515,551.00 |
| Jun 30, 2016 | 515,551.00 |
| Mar 31, 2016 | -901,928.00 |
| Mar 31, 2016 | -901,928.00 |
| Dec 31, 2015 | 496,091.00 |
| Dec 31, 2015 | 496,091.00 |
| Sep 30, 2015 | 314,712.00 |
| Sep 30, 2015 | 314,712.00 |
| Jun 30, 2015 | 444,914.00 |
| Jun 30, 2015 | 444,914.00 |
| Mar 31, 2015 | -579,583.00 |
| Mar 31, 2015 | -579,583.00 |
| Dec 31, 2014 | 345,221.00 |
| Dec 31, 2014 | 345,221.00 |
| Sep 30, 2014 | -121,365.00 |
| Sep 30, 2014 | -121,365.00 |
| Jun 30, 2014 | 565,779.00 |
| Jun 30, 2014 | 565,779.00 |
| Mar 31, 2014 | 24,975.00 |
| Mar 31, 2014 | 24,975.00 |
| Nov 30, 2013 | 6,665.00 |
| Nov 30, 2013 | 6,665.00 |
| Feb 28, 2013 | -661.00 |
| Feb 28, 2013 | -661.00 |
| Nov 30, 2012 | 5,667.00 |
| Nov 30, 2012 | 5,667.00 |
| Aug 31, 2012 | 6,937.00 |
| Aug 31, 2012 | 6,937.00 |
| May 31, 2012 | -183.00 |
| May 31, 2012 | -183.00 |